Content about Piperazines

December 20, 2011
Apothecary Shops distributes GlowCap in pilot program

Specialty pharmacy provider The Apothecary Shops is encouraging medication adherence with a cap for pill containers that cues patients with lights and sounds, the company said.

PHOENIX — Specialty pharmacy provider The Apothecary Shops is encouraging medication adherence with a cap for pill containers that cues patients with lights and sounds, the company said.

December 14, 2011
FDA advisory committee recommends approval for schizophrenia, bipolar disorder drug

A Food and Drug Administration panel has voted to recommend approval for a psychiatric drug made by Alexza Pharmaceuticals.

MOUNTAIN VIEW, Calif. — A Food and Drug Administration panel has voted to recommend approval for a psychiatric drug made by Alexza Pharmaceuticals.

October 24, 2011
FDA approves generic versions of Zyprexa

The Food and Drug Administration has approved the first generic versions of two drugs made by Eli Lilly for treating schizophrenia and bipolar disorder, the agency said Monday.

SILVER SPRING, Md. — The Food and Drug Administration has approved the first generic versions of two drugs made by Eli Lilly for treating schizophrenia and bipolar disorder, the agency said Monday.

The FDA announced the approval of generic olanzapine tablets and olanzapine orally disintegrating tablets, respectively generic versions of Lilly's Zyprexa and Zyprexa Zydus. Dr. Reddy's Labs and Teva Pharmaceuticals USA will manufacture olanzapine tablets, while Dr. Reddy's, Apotex and Par Pharmaceuticals will manufacture the orally disintegrating version.

September 28, 2011
Study: No evidence to support off-label prescribing of atypical antipsychotics

A new report from the Department of Health and Human Services' Agency for Healthcare Research and Quality found little evidence to support the use of atypical antipsychotic drugs for uses other than those for which they have official approval.

ROCKVILLE, Md. — A new report from the Department of Health and Human Services' Agency for Healthcare Research and Quality found little evidence to support the use of atypical antipsychotic drugs for uses other than those for which they have official approval.

August 30, 2011
FDA approves Perrigo, Cobrek dermatitis drug

The Food and Drug Administration has approved a treatment for dermatitis made by Perrigo under a collaboration with Chicago-based Cobrek Pharmaceutical.

ALLEGAN, Mich. — The Food and Drug Administration has approved a treatment for dermatitis made by Perrigo under a collaboration with Chicago-based Cobrek Pharmaceutical.

The drug maker said Tuesday that the FDA approved ketoconazole foam in the 2% strength. The drug is a generic version of Stiefel Labs' Extina, a topical drug used to treat seborrheic dermatitis in patients ages 12 years and older with healthy immune systems.

Extina has annual sales of about $10 million, according to Perrigo.

August 18, 2011
Sato launches motion-sickness thin-strip solution

Sato Pharmaceutical on Wednesday launched Zentrip, a new motion-sickness product featuring a fast-dissolving, fast-acting, citrus-flavored meclizine hydrochloride thin-strip.

TORRANCE, Calif. — Sato Pharmaceutical on Wednesday launched Zentrip, a new motion-sickness product featuring a fast-dissolving, fast-acting, citrus-flavored meclizine hydrochloride thin-strip.

May 24, 2011
Taro gets nod to market generic Zyrtec for kids

The Food and Drug Administration has approved a generic over-the-counter treatment for allergies made by Taro Pharmaceutical Industries.

HAWTHORNE, N.Y. — The Food and Drug Administration has approved a generic over-the-counter treatment for allergies made by Taro Pharmaceutical Industries.

Taro announced Monday the approval of cetirizine hydrochloride oral solution.

The drug, a generic version of Johnson & Johnson’s children’s Zyrtec, is used to relieve symptoms of indoor and outdoor allergies and is available in a sugar-free bubblegum flavor.

May 18, 2011
Medco: Cancer drugs to see huge rise by 2013

Cancer drugs are expected to see sharp increases in spending and use by 2013, according to the latest drug trend report by pharmacy benefit manager Medco Health Solutions.

ORLANDO, Fla. — Cancer drugs are expected to see sharp increases in spending and use by 2013, according to the latest drug trend report by pharmacy benefit manager Medco Health Solutions.

The overall drug trend for 2010 was 3.7%, lowered by higher rates of generic drug dispensing; more than 71% of drugs dispensed were generics. Specialty drugs, mostly branded biologics, accounted for 70.1% of the overall drug trend, with especially strong growth in cancer drugs, whose drug trend reached 21.2%.

March 30, 2011
Prestige Brands introduces new allergy product

Prestige Brands on Wednesday announced the launch of a new one-dose-per-day allergy medicine — PediaCare 24-hour allergy.

IRVINGTON, N.Y. — Prestige Brands on Wednesday announced the launch of a new one-dose-per-day allergy medicine: PediaCare 24-Hour Allergy.

"We listened to what the moms were looking for: a safe and effective allergy product for their children, ages 2 years and up, that works, has only one dose per day and tastes good," stated Sherry Polevoy, PediaCare senior brand manager. "Parents don't have to worry about redosing during the day, it's dye-free and it's a flavor that kids love: grape."

February 23, 2011
Forest to acquire Clinical Data

Drug maker Forest Labs plans to acquire the developer of a recently approved antidepressant.

NEW YORK — Drug maker Forest Labs plans to acquire the developer of a recently approved antidepressant.

Forest announced that it would pay $1.2 billion, or $30 per share, to acquire Clinical Data, saying the acquisition would give it control of the drug Viibryd (vilazodone hydrochloride), a treatment for major depressive disorder in adults that won Food and Drug Administration approval last month. The agreement also includes up to $6 per share in addition for milestones related to Viibryd.

February 17, 2011
FDA OKs Abilify as maintenance treatment for bipolar disorder

The Food and Drug Administration has approved a psychiatric drug for treating bipolar disorder when used in combination with one of two other drugs.

PRINCETON, N.J. — The Food and Drug Administration has approved a psychiatric drug for treating bipolar disorder when used in combination with one of two other drugs.

The FDA approved Abilify (aripiprazole), made by Bristol-Myers Squibb and Otsuka Pharmaceutical, as an adjunct to lithium or valproate for maintenance treatment of bipolar I disorder.

January 24, 2011
In study, Alexza's schizophrenia treatment significantly improves symptoms

An investigational schizophrenia drug appears effective in reducing agitation in patients with the disease, according to results of a late-stage clinical trial published in the British Journal of Psychiatry.

MOUNTAIN VIEW, Calif. — An investigational schizophrenia drug appears effective in reducing agitation in patients with the disease, according to results of a late-stage clinical trial published in the British Journal of Psychiatry.

Alexza Pharmaceuticals announced results of a phase-3 trial of the inhaled drug AZ-004 (loxapine), which showed statistically significant improvement in symptoms of agitation in patients compared with the placebo.

October 27, 2010
FDA OKs expanded use of Sprycel

The Food and Drug Administration has approved a new usage for a blood cancer drug,...

July 20, 2010
Fera acquires rights to investigational otomycosis treatment

Fera Pharmaceuticals has acquired rights to an investigational drug for treating a rare fungal ear...

July 18, 2010
Reporters Notebook

Metabolex has entered an agreement to discover and develop Type 2 diabetes drugs with a...

July 11, 2010
Sprycel receives priority review from FDA

A cancer drug made by Bristol-Myers Squibb and Otsuka Pharmaceutical has received priority review from...

June 17, 2010
Novartis’ Tasigna receives nod from FDA

The Food and Drug Administration has approved a drug as an early treatment for a...

May 13, 2010
Prescription Solutions study: Use of AAs up diabetes risk in elderly

Off-label use of atypical antipsychotics may increase the risk of developing diabetes among the elderly,...

February 18, 2010
Novartis' Tasigna receives priority review from FDA

The Food and Drug Administration will shorten its review time of a Novartis drug under...

February 16, 2010
Giant Eagle free antibiotics program proves a winner

Giant Eagle last week announced that its free antibiotics program, launched in September of last...

PITTSBURGH Giant Eagle last week announced that its free antibiotics program, launched in September of last year, has resulted in more than $3 million in free prescriptions for customers in the company's four-state operating area.

January 12, 2010
Study finds no adverse effect of antipsychotics on blood sugar, cholesterol levels

Despite a warning from the Food and Drug Administration, blood sugar and cholesterol monitoring of...